Unveiling the Latest Evidence: CGM’s Evolving Impact on Diabetes Care

This article provides a comprehensive summary of the latest evidence on continuous glucose monitoring (CGM) and its evolving impact on diabetes care. Read here to learn why increased implementation and expanded use of CGM’s should improve clinical outcomes and reduce diabetes-related health care costs.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Unveiling the Latest Evidence: CGM’s Evolving Impact on Diabetes Care

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

$20 Billion National Strategy Aims to Close the Women's Health Gap

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Unveiling the Latest Evidence: CGM’s Evolving Impact on Diabetes Care

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

$20 Billion National Strategy Aims to Close the Women's Health Gap

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care